Table 4 Univariate and multivariate analysis of OS in patients with LM (n = 62).

From: Furmonertinib combined with bevacizumab in EGFR-TKI-resistant leptomeningeal metastasis: analysis of the CSF ctDNA molecular response and survival outcomes

Variables

Univariate

Multivariate

HR (95% CI)

P

HR (95% CI)

P

Age (<60 years vs. ≥60 years)

0.821 (0.412–1.635)

0.574

  

Sex (male vs. female)

0.711 (0.493–1.026)

0.068

  

TP53 mutation in CSF

0.842 (0.426–1.666)

0.622

  

(yes vs. no)

Smoking status (yes vs. no)

0.618 (0.256–1.493)

0.285

  

ECOG PS (2 vs.3–4)

0.425 (0.193–0.935)

0.033

0.405 (0.183–0.896)

0.026

Concurrent brain metastases

1.352 (0.701–2.610)

0.368

  

Concurrent bone metastases

1.860 (0.771–4.490)

0.168

  

Treatment lines (≤3 vs. >3)

0.948 (0.491–1.832)

0.874

  

Treatments of LM

WBRT (yes vs. no)

0.594 (0.270–1.306)

0.195

  

Intrathecal chemotherapy

0.211 (0.099–0.452)

≤0.0001

0.200 (0.092–0.433)

≤0.0001

(yes vs. no)

  1. OS overall survival, LM leptomeningeal metastasis, HR hazard ratio, CI confidence interval, TP53 tumour protein p53 gene, CSF cerebrospinal fluid, ECOG PS Eastern Cooperative Oncology Group Performance Status, WBRT whole-brain radiotherapy.
Back to article page